Get to know our clinical trials
Open-label, multicenter extension trial for patients who participated in previous clinical studies of ASTX727 (standard dose).
THE OBJECTIVE OF THE STUDY IS TO PROVIDE CONTINUED TREATMENT WITH ASTX727 TO STUDY PATIENTS WHO BENEFITED FROM ASTX727 TREATMENT IN A PREVIOUS STUDY OR WHO COULD BENEFIT FROM ADDITIONAL ASTX727 TREATMENT.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- OPEN-LABEL, MULTICENTER EXTENSION STUDY FOR PATIENTS WHO PARTICIPATED IN PREVIOUS CLINICAL STUDIES OF ASTX727 (STANDARD DOSE).
- Code EudraCT: 2018-003942-18
- Protocol number: ASTX727-06
- Promoter: Astex Pharmaceuticals, Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.